NCT04685512View on ClinicalTrials.gov

Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

April 1, 2021

Study Completion Date

May 1, 2021

Conditions
Covid19
Interventions
DRUG

tenofovir disoproxil and emtricitabine

Experimental drugs administration of 7-day short course TDF/FTC

Trial Locations (2)

14000

Caen University Hospital, Caen

45100

Regional Hospital, Orléans

All Listed Sponsors
lead

University Hospital, Caen

OTHER

NCT04685512 - Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home | Biotech Hunter | Biotech Hunter